

NCT03663387 comparison:

Summary:
CHIA has 27 criteria while your personal folder has 27 criteria
Total found criteria: 22/27
Total not Found: 5/27
Total Extra: 8
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male and female subjects between 40-85 years old   │ Male and female subjects between 20-100 years old  │
│ will be enrolled. Younger subjects are not         │ will be enrolled. Younger subjects are not         │
│ included as the risk for brain amyloid lesions is  │ included as the risk for brain amyloid lesions is  │
│ too low                                            │ too low                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ All subjects will be in good general health and    │ All subjects will be in good general health and    │
│ able to participate in the LP and imaging exams.   │ able to participate in the LP and imaging exams.   │
│ This determination is made by the study            │ This determination is made by the study            │
│ neurologist and reviewed at a consensus meeting    │ neurologist and reviewed at a consensus meeting    │
│ for each subject                                   │ for each subject                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled hypertension or metabolic disease     │ Uncontrolled hypertension or metabolic disease     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Neurodegenerative disorders (i.e. Parkinson        │ Neurodegenerative disorders (i.e. Parkinson        │
│ disease. LBD, or FTD)                              │ disease. LBD, or FTD)                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Long-life DSM-IV axis 1 disorders                  │ Long-life DSM-IV axis 1 disorders                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Mental retardation                                 │ Mental retardation                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Substance abuse                                    │ Substance abuse                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concurrent medication limiting validity of         │ Concurrent medication limiting validity of         │
│ neuropsychological tests or imaging                │ neuropsychological tests or imaging                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Anti-depressants with anti-cholinergic properties  │ Anti-depressants with anti-cholinergic properties  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Monoamine oxidase inhibitors (MAOi)                │ Monoamine oxidase inhibitors (MAOi)                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Regular use of narcotic analgesics (>2 doses per   │ Regular use of narcotic analgesics (\>2 doses per  │
│ week)                                              │ week)                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of neuroleptics                                │ Use of neuroleptics                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Individuals taking over the counter memory         │ Individuals taking over the counter memory         │
│ enhancing or protecting medications (e.g. ginkgo   │ enhancing or protecting medications (e.g. ginkgo   │
│ biloba, vitamins) are not excluded                 │ biloba, vitamins) are not excluded                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Implanted medical devices that are incompatible    │ Implanted medical devices that are incompatible    │
│ with MRI imaging                                   │ with MRI imaging                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Radiation exposures exceeding annual Rad Worker    │ Radiation exposures exceeding annual Rad Worker    │
│ limits                                             │ limits                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Heart failure stage D as defined by American Heart │ Heart failure stage D as defined by American Heart │
│ Association (7)                                    │ Association (7)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic kidney disease in stages = 4, as defined   │ Chronic kidney disease in stages ≥ 4, as defined   │
│ per National Kidney Foundation (8)                 │ per National Kidney Foundation (8)                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Brain tumor and other neoplastic disorders outside │ Brain tumor and other neoplastic disorders outside │
│ the brain where disease itself or its treatment    │ the brain where disease itself or its treatment    │
│ (radiation, chemotherapy) is likely to affect      │ (radiation, chemotherapy) is likely to affect      │
│ brain structure or function                        │ brain structure or function                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Stroke when meeting criteria for total anterior,   │ Stroke when meeting criteria for total anterior,   │
│ partial anterior or posterior circulation infarct  │ partial anterior or posterior circulation infarct  │
│ according to the Oxford Community Stroke Project   │ according to the Oxford Community Stroke Project   │
│ classification. Patients with clinically silent of │ classification. Patients with clinically silent of │
│ lacunar strokes and transient ischemic attacks     │ lacunar strokes and transient ischemic attacks     │
│ will not be excluded                               │ will not be excluded                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant head trauma                            │ Significant head trauma                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hydrocephalus                                      │ Hydrocephalus                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hostility or refusal to cooperate                  │ Hostility or refusal to cooperate                  │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ All subjects will speak English as their first language or demonstrate proficiency in English        │
│ (defined as reaching a scaled score of > 11 on the WAIS vocabulary test)                             │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ All subjects will have normal cognition at baseline: a Clinical Dementia Rating CDR=0, Global        │
│ Deterioration Scale GDS<2                                                                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Dementia or Mild cognitive impairment at baseline                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Long life major depression. Baseline scores =16 on the 17-item Hamilton Depression Scale at baseline │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Use of anti-dementia medications (Aricept, Exelon, Razadyne) and memantine (Namenda)) or anti-       │
│ Parkinsonian medications (Sinemet, amantadine, bromocriptine, pergolide, selegeline)                 │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                             │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ All subjects will speak English as their first language or demonstrate proficiency in English       │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Person's receiving chronic anti-coagulation therapy                                                 │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Long life major depression. Baseline scores ≥20 on Beck Depression Inventory at baseline            │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Participants in this study will be allowed to participate in other observational research studies.  │
│ The investigators will review at enrollment the full array of projects a subject may be involved in │
│ and inform the other PI's to ensure that subject safety and research data integrity is not          │
│ compromised                                                                                         │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 100 Years                                                                  │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 20 Years                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Person's participating in other research projects will be excluded when the other project(s) 1)     │
│ involve radiation exposure which in combination with the current project would increase radiation   │
│ exposure above federal guidelines, 2) involve administration of study drug or other experimental    │
│ therapy, or 3) prohibit participation in other research projects                                    │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ All subjects may have normal cognition or cognitive impairment                                      │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛